Clinical Trial Update: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating letermovir for prevention of cytomegalovirus reactivation in patients with hematologic malignancies treated with alemtuzumab; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Prolymphocytic Leukemia
• Chronic Lymphocytic Leukemia
• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma
• Sezary Syndrome
• T-cell Prolymphocytic Leukemia

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2024-07-18